Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page adds new participant-focused sections (How to Read a Study Record, Common Questions, How to Join a Study) and marks recruitment as No longer looking for participants. The Intervention/Treatment label is updated and the revision tag advances to v3.6.0, replacing v3.5.5.SummaryDifference0.4%

- Check16 days agoChange DetectedThe page shows Revision: v3.5.5, replacing v3.5.4, indicating a small update to the study record's metadata rather than substantive content changes.SummaryDifference0.0%

- Check37 days agoChange DetectedThe study record version was updated from v3.5.3 to v3.5.4, representing a minor maintenance update to the ClinicalTrials.gov page. This change does not alter the study design, endpoints, eligibility criteria, or reported information.SummaryDifference0.0%

- Check52 days agoChange DetectedThe sponsor line now shows Resilient Pharmaceuticals as sponsor and responsible party, replacing Lykos Therapeutics. This change reflects a shift in the organization overseeing the study.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page’s footer revision marker was updated from v3.5.2 to v3.5.3, indicating a general platform/version change without affecting the listed clinical trial study information.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.